Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock
Rinaldo Bellomo, Richard G Wunderink, Harold Szerlip, Shane W English, Laurence W Busse, Adam M Deane, Ashish K Khanna, Michael T McCurdy, Marlies Ostermann, Paul J Young, Damian R Handisides, Lakhmir S Chawla, George F Tidmarsh, Timothy E Albertson
Critical Care | BMC | Published : 2020
BACKGROUND: In patients with vasodilatory shock, plasma concentrations of angiotensin I (ANG I) and II (ANG II) and their ratio may reflect differences in the response to severe vasodilation, provide novel insights into its biology, and predict clinical outcomes. The objective of these protocol prespecified and subsequent post hoc analyses was to assess the epidemiology and outcome associations of plasma ANG I and ANG II levels and their ratio in patients with catecholamine-resistant vasodilatory shock (CRVS) enrolled in the Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) study. METHODS: We measured ANG I and ANG II levels at baseline, calculated their ratio, and compared the..View full abstract
The original study and the prespecified and post hoc analyses were funded by La Jolla Pharmaceutical Company. La Jolla Pharmaceutical Company was involved in the design of the study; the collection, analysis, and interpretation of data; and the writing of the manuscript.